Menu

Notable Science Quotes

14-day-old embryos, prioritizing biodiversity, and more

Jun 1, 2016
The Scientist Staff

TESTING THE LIMITS: An artificially colored MRI of a 13-day-old human blastocyst implanted in the uterine wall© ANATOMICAL TRAVELOGUE/SCIENCE SOURCE

The 14-day rule was never intended to be a bright line denoting the onset of moral status in human embryos. Rather, it is a public-policy tool designed to carve out a space for scientific inquiry and simultaneously show respect for the diverse views on human-embryo research.

Insoo Hyun et al., in a Nature commentary questioning the internationally agreed 14-day limit on human embryo research after two groups reported growing human embryos in vitro for 12–13 days (May 4)

 

What if scientists could culture the human embryo for longer than 14 days? Perhaps we could begin to understand the consequences of fetal alcohol syndrome, study the potential causes of autism and find out why some environmental chemicals can affect development. Perhaps we might, for example, be able to more quickly understand what the Zika virus does to embryos to cause major problems with brain development. There could be major benefits for society, but if the 14-day line is crossed then society has to fully understand the science and come to an informed decision about the use of the technology.

Peter Donovan, biologist at the University of California, Irvine, in response to the recent Nature commentary questioning the internationally agreed 14-day limit on human embryo research (May 4)

 

I am rock solid about my research. I know it is very good. But this wastebook targeted a short paper that was the first paper in my young graduate student’s career.

—Duke University biologist Sheila Patek, at an April event in Washington, DC, discussing the ramifications of her mentee’s mantis shrimp research being included in Senator Jeff Flake’s (R-AZ) “wastebook,” which is designed to highlight what he deems to be unnecessary federally funded science (April 13)

 

This has been enlightening, and we want to make sure we are accurate. It is a learning process.

—Senator Jeff Flake (R-AZ), sharing his thoughts on an April meeting where several of the researchers targeted by his “wastebook” gathered to discuss their maligned projects and educate Congressional staffers on the utility of their federally funded science (April 13)

 

We can’t save every species, of course. The planet is losing its biodiversity at an alarming rate, and there are too many species circling the drain. Conservation professionals acknowledge that we will need to perform a sort of conservation triage, a painful process of deciding which species to try to rescue and which to let go.

—Journalist Hillary Rosner, in a New York Times opinion piece about the efforts of biotechnologists to conserve Earth’s biodiversity (April 16)

 

Many of my most talented graduate students that I’ve trained with PhDs in molecular biology and biochemistry have gone on to be lawyers, venture capitalists, you name it. I think that’s great! Because they never forget their scientific training, and to me that’s worth every effort. So that’s why I say, no, we need more PhDs, not fewer.

Robert Tjian, president of the Howard Hughes Medical Institute, on the need for increased scientific training in the U.S. (April 28)

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.